



## PRELIMINARY PROGRAM

### Thursday July the 15th, 2010

11:00 am	Registration Opens
01:30 - 02:00 pm	Introduction and Welcome Welcome: Dr. Rafael de la Torre Program Overview: Dr. Terrence J. Monks
02:00 - 03:00 pm	Keynote Lecture Dr. Robert Snyder, Rutgers University, Piscataway, NJ, USA
03:00 - 03:30 pm	Coffee Break

#### Session I: BRIs and New Reactive Intermediate Chemistry (Chair, Dr. Dave Williams, Oregon State Univ)

03:30 - 04:00 pm	Dr. M.W. Anders, Dept. of Pharmacology and Physiology, University of Rochester Medical Center, Rochester, NY, USA. " <i>Putting Bioactivation Studies to Work: Targeting Antioxidants to Mitochondria.</i> "
04:00 - 04:30 pm	Dr. Reinald Pamplona, Dept. of Experimental Medicine, University of Lleida-IRBLLEIDA, Lleida, Spain, " <i>Advanced Lipoxidation End-Products (ALEs).</i> "
04:30 - 05:00 pm	Dr. Paul Ortiz de Montellano, Dept. of Pharmaceutical Chemistry, University of California, San Francisco, USA. " <i>Bioactivation of Anti-Tuberculosis Pro-Drugs by Bacterial and Mammalian Flavin Monooxygenases.</i> "
05:00 - 05:30 pm	Dr. Stacy Simonich, University of Oregon, " <i>Perinatal Exposure in Humans to Bioactivated Polycyclic Aromatic Hydrocarbons.</i> "
05:30 pm	Opening Reception

### Friday July the 16<sup>th</sup>, 2010

#### Session II: Toxicological Consequences of Reactive Metabolite Formation (Chair, Dr. Peter Moldeus, Astra-Zeneca, Stockholm)

08:30 - 09:00 am	Dr. Osamu Okazaki, Daiichi-Sakyo Co, Tokyo, Japan. " <i>A classification system for risk assessment of idiosyncratic drug toxicity using daily dose and covalent binding.</i> "
09:00 - 09:30 am	Dr. Kevin Park: MRC Drug Safety Centre, University of Liverpool, UK, " <i>Mechanistic role of protein adduct formation.</i> "
09:30 - 10:00 am	Dr. John Hayes: University of Dundee, UK, " <i>Cellular defence against reactive intermediates and its role in disease susceptibility.</i> "
10:00 - 10:30 am	Dr. Amit Kalgutakar, Pfizer Global Research & Development, New York, USA, " <i>Chemical Toxicophores: Potential for Trouble.</i> "
10:30 - 11:00 am	Coffee Break and Poster Session Viewing

#### Session III: Strategies for Managing Reactive Intermediates in Drug Discovery and Drug Development (Chair, Dr. Tom Baillie, University of Wash, Seattle)

11:00 - 12:30 pm	Dr. Griff Humphries, Bristol Myers Squibb, Princeton, NJ, USA - " <i>Strategies for addressing BRIs in drug discovery and lead optimization.</i> " Dr. Stephen Clarke, Glaxo Smith Kline, Ware, UK - " <i>Strategies for addressing BRIs in preclinical and clinical development.</i> " Dr. Richard Thompson, AstraZeneca, Mölndal, Sweden - " <i>Risk assessment and mitigation strategies for BRIs in drug discovery and development.</i> "
12:30 - 01:00 pm	Panel Discussion
01:00 - 02:00 pm	Lunch and Poster Session Viewing

#### Session IV: Platform Session I - selected from submitted abstracts based upon relevance to programmatic themes.

02:00 - 03:30 pm	Oral presentations
03:30 - 04:00 pm	Coffee Break and Poster Session Viewing

#### Session V: Natural/Dietary products and BRIs (Chair, Dr. Judy Bolton, UIC, Chicago)

04:00 - 04:30 pm	Dr. Judy Bolton, UIC, Chicago, USA - " <i>BRIs formed from botanical dietary supplements.</i> "
04:30 - 05:00 pm	Dr. Hansruedi Glatt, German Institute of Human Nutrition (DIFE) Potsdam-Rehbruecke, Department of Nutritional Toxicology, Nuthetal, Germany. " <i>Consumption of brassica vegetable leads to the formation of high levels of DNA adducts in vivo - caused by highly mutagenic glucosinolates.</i> "
05:00 - 05:30 pm	Dr. Ivonne Rietjens, University of Wageningen, The Netherlands - " <i>Flavonoids and alkenylbenzenes; new concepts in bioactivation studies.</i> "
05:30 pm	Dr. Andrew Mesecar, UIC, Chicago, USA - " <i>The role of the Keap1-Nrf2-Cul3 system in cancer chemoprevention by natural products.</i> "



### Saturday July the 17<sup>th</sup>, 2010

**Session VI:** Cellular & Molecular Responses to BRIs (Chair, Dr. Donna Zhang University of AZ, Tucson)

- 08:30 – 09:00 am Dr. Dolores Pérez-Sala, Chemical and Physical Biology Department, Centro de Investigaciones Biológicas, C.S.I.C. Ramiro de Maeztu, 9 28040 Madrid, Spain. "TBA"
- 09:00 – 09:30 am Dr. Donna D. Zhang, University of Arizona, Tucson, AZ, USA "TBA"
- 09:30 – 10:00 am Dr. Antonio Cuadrado, Universidad Autónoma de Madrid, Spain "TBA"
- 10:00 – 10:30 am Author/s to be confirmed, "Activation of the NRF2 signaling pathway by redox cycling of para- and ortho-hydroquinones"
- 10:30 – 11:00 am Coffee Break and Poster Session Viewing

**Session VII:** Platform Session I – selected from submitted abstracts based upon relevance to programmatic themes.

- 11:00 – 12:30 am Oral presentations  
AFTERNOON FREE

### Sunday July the 18<sup>th</sup>, 2010

**Session VIII:** BRIs - Proteomics Approaches (Chair, Dr. Serrine S. Lau, University of AZ, Tucson)

- 08:30 – 09:00 am Dr. Dennis Petersen, University of Colorado, Denver, CO, USA "*Lipid peroxidation products and protein modifications*".
- 09:00 – 09:30 am Dr. Feixia Chu, Hubbard Center for Genome Studies, University of New Hampshire, USA. "*Histone Modifications*"
- 09:30 – 10:00 am Dr. Jonathan Doorn, University of Iowa, Iowa City, USA. "*Dopamine-derived BRIs and protein modifications – implications for Parkinson's Disease*".
- 10:00 – 10:30 am Dr. Serrine Lau, University of Arizona, Tucson, AZ, USA " *BRI-derived protein adducts as biomarkers of diabetic complications*"
- 10:30 – 11:00 am Coffee Break and Poster Session Viewing

**Session IX:** Environmental Exposures to BRIs and their Impact on Human Health.

**The Spanish Toxic Oil Syndrome – 30 Years After**

Chair: Dr. Àngel Messeguer

- 11:00 – 11:10 am Dr. Emilio Gelpí, Past Chairman of the WHO Scientific Committee for the Toxic Oil Syndrome: "*Introduction to the Toxic Oil Syndrome. Onset, clinical picture and working hypothesis*"
- 11:10 – 11:35 am Dr. Angel Messeguer Peypoch, Director, Centro de Investigacion y Desarrollo Pascual Vila, Barcelona, Spain: "*Potential implication of aniline derivatives in TOS*"
- 11:35 – 12:05 am Dr. M. Victoria Ruíz-Méndez, Instituto de la Grasa of the Spanish Council for Scientific Research (CSIC), Seville, Spain, "*Contribution of denaturing and deodorization processes of oils to TOS*"
- 12:05 – 12:30 am Dr. Emilio Gelpí, CSIC/UAB Proteomics Laboratory, Instituto de Investigaciones Biomédicas de Barcelona-Consejo Superior de Investigaciones Científicas, IDIBAPS, Barcelona Autonomous University, Spain. "*Proteomics of TOS in Humans*"
- 12:30 – 01:30 pm Lunch and Poster Session Viewing

**Benzene, 1,3-Butadiene and BRIs: Lessons Learned and The Way Ahead.**

Chair: Dr. David Ross, University of Colorado, Denver, CO, USA

- 01:30 – 02:00 pm Dr. David Ross, University of Colorado, Denver, Aurora, CO, USA "*Benzene and 1,3-butadiene. BRI's and Susceptibility Factors*"
- 02:00 – 02:30 pm Dr. Leslie Recio, Integrated Lab Systems, Durham, NC, USA "TBC"
- 02:30 – 03:00 pm Dr. James A Swenberg, University of North Carolina, Chapel Hill, NC, USA "TBC"
- 03:00 – 03:30 pm Dr. Martyn Smith, Environmental Health Sciences, School of Public Health, University of California, Berkeley, CA, USA. "*Benzene, Exposomics and the Way Ahead*"
- 03:30 – 04:00 pm Coffee Break and Poster Session Viewing
- 04:00 – 04:20 pm Closing Comments and Future Directions - TBA
- 04:30 pm Closing Reception